Source comparison
CJC-1295 vs Ipamorelin FAQs
CJC-1295 is a GHRH analog that amplifies existing growth hormone pulses through the GHRH receptor. Ipamorelin is a ghrelin receptor agonist that initiates new GH pulses. They act on two different receptors in the pituitary, which is why they are typically stac
This comparison does not assign a generated winner or score.
- CJC-1295 is a GHRH analog that amplifies existing growth hormone pulses through the GHRH receptor. Ipamorelin is a ghrelin receptor agonist that initiates new GH pulses. They act on two different receptors in the pituitary, which is why they are typically stacked together.
- They activate complementary arms of the GH axis. CJC-1295 amplifies the hormone-releasing signal while Ipamorelin triggers the pulse. Together they may produce larger, more physiological GH output than either peptide alone, mimicking the natural dual-signal control system more closely.
- Individually, Ipamorelin typically produces a more acute GH spike, while CJC-1295 (especially with DAC) provides sustained GH elevation over a longer period. The combination is studied because acute pulses plus sustained amplification may yield the most robust overall GH and IGF-1 response.
- Ipamorelin is considered the most selective GH secretagogue, with minimal effects on cortisol, prolactin, or appetite. CJC-1295 without DAC is also well-tolerated in research. The DAC version may cause more sustained effects due to its extended half-life of approximately 8 days.